GlassScriptPhysician profile
Debora Duro
NPI 1194716761
$25,918.17
in general payments reported to CMS, 2019-2025
8 companies · $2,704 in 2025
The $2,704 reported for 2025 was more than what 88% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,746 · 2021: $74.54 · 2022: $12K · 2023: $230 · 2024: $3,478 · 2025: $2,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,025 · Consulting Fee: $230 · Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,025.00 |
| Consulting Fee | $230.00 |
| Food and Beverage | $156.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $10,441.75 | 2019-2023 | Smoflipid |
| Alcresta Therapeutics, INC. | $6,025.00 | 2024-2025 | Relizorb |
| Shire North American Group INC | $5,732.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,471.25 | 2019-2022 | |
| Mirum Pharmaceuticals, INC. | $94.93 | 2024-2025 | Livmarli, Cholbam, Chenodal |
| Intuitive Surgical, INC. | $90.32 | 2022 | |
| Capsovision, INC. | $41.24 | 2025 | Capsocam Plus |
| Applied Medical Technology INC | $20.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Duro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.